FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/06/2022
Voltar para busca
Dado oficial do USPTO
CURIGIN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CURIGIN
ST13
US500000079288213Classe
5, 35, 42, 44
Pedido
79288213
Registro
6585328
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
21/06/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35, 42, 44
Data de depósito
21/04/2020
Data de registro
14/12/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/12/2021
Última transação
14/12/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
KR
Examinador
BRADLEY, EVELYN
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Curigin Co., Ltd
Representantes
Eric S. Hyman Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Biopharmaceuticals for the prevention of cancer; biopharmaceuticals for the diagnosis of cancer; biopharmaceuticals for the treatment of cancer; biopharmaceuticals in the form of cancer oncolytic virus for the prevention of cancer; biopharmaceuticals in the form oncolytic virus for the diagnosis of cancer; biopharmaceuticals in the form of oncolytic virus for the treatment of cancer; Drugs for medical purpose for the treatment of cancer and non-cancerous diseasesrespiratorymetabolicneurologicalophthalmologicalgastrointestinalcardiovascularskinurogenitalgynecologicalendocrinehead and neckskeletalautoimmune and rare diseases; Veterinary preparations for the treatment of cancer and non-cancerous diseasesrespiratorymetabolicneurologicalophthalmologicalgastrointestinalcardiovascularskinurogenitalgynecologicalendocrinehead and neckskeletalautoimmune and rare diseases; anti-cancer preparations; antiulcerants; vaccines; pharmaceutical preparations and substances for the prevention of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical compounds for treating cancer; pharmaceuticals for viral and non-viral vector-based gene therapy; medicine for viral and non-viral vector-based gene therapy for human purposes; antibiotics; dietary supplements; dietetic nutritionally fortified food adapted for medical purposes; insecticides; fungicides
Classe 35
Providing commercial information and consumer product information; import-export agency services; sales agency servicessales promotion for others in the field of apparatus for use in medical analysis; arranging sales events for others in the field of apparatus for use in medical analysis; sales agency servicessales promotion for others in the field of pharmaceuticals; arranging sales events for others in the field of pharmaceuticals; business intermediary services in the nature of purchasing pharmaceuticals for others relating to mail order by telecommunications; procurement of contracts for the purchase and sale of goods and services; advertising services; advertising services relating to pharmaceutical products; business intermediary services in the nature of matching purchasers with sellers of goods and services for the sale and purchase of goods and services
Classe 42
Research relating to biotechnology; scientific research for medical purposes in the field of cancerous diseases; research relating to pharmaceuticals; research in the field of medical products; medical research services; conducting clinical trials for others; clinical studies in the nature of medical research; development of new technology for others in the field of biotechnology; scientific research for medical purposes in the area of cancerous diseases; development of medical products; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; conducting clinical research in the field of medicines; clinical trials of medicinesfor others; software design and development; computer programming for others in the medical field
Classe 44
Providing health informationnot including dentistry; healthcare information services relating to the use of medical products for the preventiondiagnosis and treatment of cancer and non-cancerous diseases; medical and pharmaceutical consultancy; consultancy services relating to pharmaceutical products for the preventiondiagnosis and treatment of cancer and non-cancerous diseases; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceutical products for the preventiondiagnosis and treatment of cancer and non-cancerous diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
25/05/2022
FIMP
FINAL DISPOSITION PROCESSED
24/05/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
14/03/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
19/12/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
14/12/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/12/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/12/2021
GPNX
NOTIFICATION PROCESSED BY IB
25/10/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/09/2021
PUBO
PUBLISHED FOR OPPOSITION
28/09/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/09/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/09/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/08/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
25/08/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
25/08/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
25/08/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
25/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/08/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/08/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/08/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/04/2021
GNFR
FINAL REFUSAL E-MAILED
08/04/2021
CNFR
FINAL REFUSAL WRITTEN
08/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/02/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/02/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/02/2021
RFNT
REFUSAL PROCESSED BY IB
27/09/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/09/2020
RFRR
REFUSAL PROCESSED BY MPU
25/08/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/07/2020
CNRT
NON-FINAL ACTION WRITTEN
18/07/2020
DOCK
ASSIGNED TO EXAMINER
13/07/2020
MAFR
APPLICATION FILING RECEIPT MAILED
30/06/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/06/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
25/06/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CURIGIN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.